Angel Biotechnology Holdings plc (ABH.L) said it has signed a Framework Agreement with TransGenRx Inc. The purpose of the framework agreement is to outline the process whereby Angel will manage the development, scale up and manufacture of a recombinant protein product.
It is planned that the framework agreement will form the basis of future technical and commercial agreements whereby Angel will utilise its GMP facility at Cramlington to expedite and optimise the expression systems provided by TransGenRx Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.